Period October - December
Period January - December
October - December in brief
· Net sales rose by 22 percent to
· Gross profit improved by 1,109 thousand to
· Operating profit before depreciation and amortization (EBITDA) totaled
· Operating earnings fell
· Comprehensive income for the period declined by
· Comprehensive income per share, basic and diluted, totaled
· Cash flow from operating activities rose by
·
· At the Extraordinary General Meeting, held on
The full year in summary
· Net sales rose 75 percent, or
· Gross profit improved by
· Operating profit before depreciation and amortization (EBITDA) totaled
· Operating profit/loss improved by
· Comprehensive income for the full year improved by
· Comprehensive income per share, basic and diluted, improved by
· Cash flow from operating activities was
Events after the end of the year
The Board decided to advance the publication of all reports in 2020 due to more efficient financial routines.
2019 - A milestone in
We ended an extremely successful 2019 with our best sales quarter ever, excluding the bioprocess deal. Sales reached almost
Operating earnings for the financial year improved significantly compared with 2018 and it is with great pleasure that for the first time my colleagues and I can report a net profit for an individual financial year.
During the fourth quarter we completed the planned investments in the production plant for enzymes used in biochemical analysis of biological drugs. The facility is designed to be able to handle the production needs of the core business area Analysis for many years to come and substantially strengthens our internal production capacity. In conjunction with the investment in the production plant we have also hired additional staff for the production team.
We are therefore well equipped to continue to expand our product portfolio at a rapid pace this year. In the fourth quarter we initiated several new projects from our pipeline that we will launch in 2020. Our collaborative effort with
Our marketing activities at conferences and through customer visits intensified in the fourth quarter and our sales and marketing organization have welcomed additional employees.
Because of these bold initiatives, our expenses increased during the fourth quarter, which is in line with our strategy of reinvesting our accumulated cash in future growth.
In 2020, our main focus will be on expanding the product portfolio and continuing to grow our revenues through investments and initiatives to strengthen
To ensure that more of our product development projects reach the market in 2020, we will hire new employees to strengthen our product development organization at the beginning of the year. To keep pace with the development of the product portfolio, we will also continue to expand our marketing organization.
As we now leave 2019 behind us and look ahead, I would like to extend a special thank you to our owners who have demonstrated their confidence in our ability to develop
For more information, please contact:
ABOUT
The Group consists of
This information is information that
Published reports can be downloaded from the
https://investor.genovis.com/en/financial-reports/
This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.
https://news.cision.com/genovis-ab/r/year-end-report-january---december-2019,c3027237
https://mb.cision.com/Main/1712/3027237/1187882.pdf
(c) 2020 Cision. All rights reserved., source